Despite improvements in diagnosis and treatment, breast-cancerassociated mortality remains high owing to clinical relapse associated with metastasis to distant organs. During primary tumour progression, breast carcinoma cells may pass through an EMT, thereby acquiring traits associated with high-grade malignancy, including motility, invasiveness and an increased resistance to apoptosis 1, 2 . Furthermore, passage of both normal and neoplastic mammary epithelial cells through an EMT confers on the cells many of the properties associated with normal mammary stem cells (MaSCs) and cancer stem cells (CSCs) respectively [3] [4] [5] . Importantly, carcinoma cells that have passed through an EMT exhibit heightened resistance to conventional chemotherapeutic agents and hence may regenerate tumour growth after initial drug treatment is halted [6] [7] [8] .
Various types of stromal cell have been found to influence the CSC state through paracrine signalling. As an example, mesenchymal stem cells contribute to the formation of CSCs by secreting prostaglandin E2 (PGE2), IL-6, IL-8 and Gro-α, which help to trigger activation of the previously latent EMT program in nearby carcinoma cells 9 . Periostin (POSTN) released by lung stromal fibroblasts fosters creation of a metastatic niche for breast cancer CSCs (ref. 10) . Some have speculated that a physical CSC niche maintained by both paracrine and juxtacrine signalling exists in colon cancers similar to the normal colon stem cell niche supported by myofibroblasts 11 . Nevertheless, a juxtacrinemediated CSC niche that maintains these cells in their stem cell state has not been described.
Tumour-associated monocytes and derived macrophages (TAMs) have been shown to be involved in many aspects of tumour initiation and progression 12, 13 . These observations have not, however, shed light on how CSCs interact with TAMs in a manner different from non-CSCs, and whether heterotypic interactions contribute to the formation and maintenance of the stem cell niche.
Some have reported that normal MaSC function requires the continuing presence of macrophage-derived factors 14 , but the nature of these factors has not been explored. Moreover, it remains unclear whether the interactions between macrophages and normal MaSCs are relevant to carcinoma pathogenesis. In the present study, we describe a key mechanism by which already-formed mammary CSCs interact with niche-forming TAMs in a contact-dependent manner to maintain their residence in the mesenchymal/stem-like state.
RESULTS

Quantitative proteomic profiling of cell-surface proteins
We and others have found extensive similarities between the stem cell program of normal MaSCs and that of mammary CSCs (refs 3-5) . Ratios highlighted in red were found to be significantly differentially expressed (P < 0.05) after standardizing and applying a moderated t-test corrected by the Benjamini-Hochberg method 17 . Gene names are labelled for known EMT marker proteins and candidates that were followed up in this study. (b) The HMLE, HMLE-Twist and HMLE-Snail cells were stained with anti-CD90 and anti-CD24 antibodies and analysed by flow cytometry. The percentage of the CD90 hi CD24 − population is shown on each plot. (c,d) The cells were FACS sorted based on CD90 and CD24 levels and seeded into 3D mammosphere medium. The numbers of mammospheres are plotted (c), and representative pictures of mammospheres formed by the indicated cell populations are shown (d). n = 3 independent experiments, data represent s.e.m. * * * P < 0.001; * * * * P < 0.0001 (Student's t-test). Source data are provided in Supplementary Table 7 .
To identify cell-surface proteins that enable normal and neoplastic mammary stem cells to interact with nearby stromal cells, we performed quantitative proteomic profiling of membrane-associated proteins before and after immortalized human mammary epithelial cells 15 (HMLEs) were forced experimentally to undergo an EMT (and thereby acquire mesenchymal and stem cell traits). We employed stable isotope labelling by amino acids in cell culture 16 (SILAC) followed by membrane-associated protein fractionation and mass spectrometry analysis (MS; Supplementary Fig. 1 ).
Plasma-membrane-and extracellular-matrix-associated proteins were represented by the most abundant peptides detected by MS (Supplementary Table 1) . We identified 2,607 proteins reproducibly with at least two peptide SILAC ratios measured in each replicate, with 460 proteins found to be either upregulated (277) or downregulated (183) significantly (P < 0.05) in the EMT/stem-like cells after applying a moderated t-test 17 . Several known EMT marker proteins, E-cadherin (CDH1), N-cadherin (CDH2), vimentin (VIM) and fibronectin (FN1), showed significant expression level changes in the expected directions, confirming the specificity of the proteomic profiling (Fig. 1a) .
We focused subsequent analyses on the CD90 protein, also known as Thy1, which was among the most strongly upregulated plasma membrane proteins (12.4-fold) following passage through an EMT. CD90 is a GPI-anchored glycoprotein and has been shown to interact with integrins displayed by adjacent cells 18, 19 . Its messenger RNA was also substantially upregulated during the EMT programs induced in HMLE cells by expression of the Twist, Snail, Slug or Zeb1 EMT transcription factors (TFs; Supplementary Fig. 2a ).
Presence of stem-like cells in the CD90
hi cell population
As human mammary epithelial cells that have undergone an EMT can acquire stem-like properties 4 , we postulated that CD90 expression was upregulated in MaSCs and breast CSCs. We analysed the geneexpression data from two published reports and found a significant enrichment of CD90 expression in freshly isolated human mammary SC and CSC fractions in primary patient tissues across multiple specimens 20, 21 ( Supplementary Fig. 2b,c) . We then examined the cell-surface antigen profile of HMLEderived cells using anti-CD90 and -CD24 antibodies. CD24 has been found to be mostly expressed in differentiated mammary epithelial in patient tumours with relapse-free survival. High CD90 expression (red line) was significantly correlated with poor prognosis in ER − (n = 457, P = 1.7 × 10 −5 ) and ER + (n = 1413, P = 0.013) breast cancer patients. The plots were generated using http://kmplot.com (probe: 213869_x_at; ref. 58) . (g) HMLER90hi cells with or without CD90 shRNA were injected orthotopically into mice and the tumour sizes were measured weekly during a course of 50 days. n = 10 mice. Knockdown of CD90 by the shRNA was confirmed by flow cytometry analysis ( Supplementary Fig. 2h ). All error bars shown indicate s.e.m. * P < 0.05; * * P < 0.01; * * * P < 0.001 (Student's t-test). cells 21 . Flow cytometry analysis revealed that 99% of HMLE-Twist cells and 18% of HMLE-Snail cells were CD90 hi CD24 − , whereas the HMLE-vector control cells contained only 0.1% cells in the same compartment (Fig. 1b) , indicating that forced expression of either the Twist or Snail EMT-TFs led to substantial increases in CD90 hi CD24
− cells. The CD90 hi CD24 − cells from the three cell lines formed mammospheres 22 with a far higher efficiency than cell populations with lower CD90 expression (Fig. 1c,d ), providing further support for the association of CD90 expression with the MaSC state.
We subsequently undertook to measure the association of tumourinitiating ability with the CD90 hi CD24 − state in HMLE cells that had been transformed with the H-RasV12 oncogene (HMLER); this ability represents the operational definition of CSCs. Sorted HMLER cells were implanted orthotopically at limiting dilutions into NOD-SCID mice. The CD90 hi CD24 − HMLER cells initiated tumours at a 60-fold higher efficiency than the bulk HMLER cells and the tumours were more invasive and metastatic; the CD90 lo populations rarely formed tumours (Fig. 2a-d) . Similar results were observed when the sorted cell populations were implanted orthotopically into Nude mice ( Supplementary Fig. 2d ). CD90
hi cells from the MB-MDA-435 human breast cancer cell line also formed larger and more aggressive tumours when compared with CD90 lo cell populations ( Supplementary  Fig. 2e-g ). Consistently, the expression level of CD90 is negatively correlated with patient survival, especially in ER − breast cancer (Fig. 2e,f) . Taken together, these data demonstrated that the CD90 marker served to enrich for CSCs in carcinoma cells of mammary origin.
Physical interaction between CD90
hi CSCs and TAMs
Reduced CD90 expression by short hairpin RNA (shRNA) knockdown resulted in delayed tumour onset and decreased tumour size ( Fig. 2h ) and expanded in monolayer culture. RFP-expressing THP1 monocytes, normally propagated in suspension, were then added above the cell monolayers. We found that the RFP + monocytes adhered in large numbers to the GFP + monolayer of HMLER90hi cells, but rarely stayed attached to the HMLER90lo cells (a 22-fold difference; Fig. 3a,b) . shRNA-mediated knockdown of CD90 in HMLER90hi cells reduced the adherent monocytes by threefold, confirming the requirement of CD90 expression on the surface of the stem-like cells for efficient physical interaction with the monocytes (Fig. 3a ,b middle panels).
Association of TAMs with CD90 hi carcinoma cells in living tissues
In the xenograft tumours formed by HMLER90hi cells, CD90 expression was most prominent at the outer edge of tumour sections, where a high density of infiltrating TAMs was observed intermingled with CD90 hi cancer cells (Fig. 3c,d ), suggesting that CD90-mediated adhesion of TAMs to CSCs also occurs in vivo.
CD90 expression has been detected in primary human breast carcinomas on invading single cells or cell clusters 24 ; in metastases the CD44 + CD90 + subpopulation represents a major phenotype 25 . Although a high TAM density in primary breast cancer has been correlated with poor prognosis [26] [27] [28] , a CSC niche involving TAMs has not been demonstrated microscopically in patient tumour tissues. We undertook to verify direct contact between TAMs and CD90 hi CSCs in patient breast cancer tissue by immunofluorescence analyses with anti-CD90 and -CD68 (a cell-surface protein expressed largely by macrophages) antibodies. Juxtaposition of CD68
+ TAMs with singleinvading CD90
hi CSCs was readily detected at the tumour-stroma interface ( Fig. 3e; Supplementary Fig. 3a) . Indeed, 24-51% of observed CD90 hi cancer cells showed the presence of TAMs in close contact; in contrast, very few (0-5%) CD90
− cytokeratin + (CTK + ) cells were localized adjacent to TAMs (Fig. 3f,g; Supplementary Fig. 3b ). This direct visualization of the CSC-TAM juxtaposition in patient samples provided further support for the notion that CSCs and TAMs engage in direct contact in human breast tumours, where the latter cells help to form a niche for the CSCs.
We then expanded our analysis to include 25 core biopsy samples from patient tissues with invasive ductal carcinoma obtained during initial diagnostic core biopsies. Most CD90 + carcinoma cells showed reduced levels of cytokeratin expression, consistent with their passage through an EMT (Supplementary Fig. 3c ). The number of CD68 + TAMs per microscopic field correlated with the number of CD90 + CTK − CSCs (r = 0.44, P = 0.002) but not with CD90 − CTK + non-CSCs (r = −0.12, P = 0.60; Fig. 3h ). This indicated that TAMs often infiltrate CD90 + CSC-rich areas, allowing the juxtacrine signalling to occur. Accordingly, we could observe intermingling of CD68 + TAMs with CD90 + CSCs, but the macrophages rarely infiltrated into islands of CD90 − CTK + non-CSCs (Fig. 3i) . Finally, consistent with this, analysis of the TCGA invasive breast carcinoma data set revealed that CD90 expression in breast tumours positively correlated with CD68 expression (Supplementary Fig. 3e ).
Monocytes/macrophages facilitate tumour outgrowth by the CSCs
Monocytes and macrophages in tumours have great functional plasticity 12, 29 . To test whether the CSC-TAM interaction that we observed is important to tumour formation, we depleted endogenous macrophages in the mammary fat pads at the time of implantation by co-injecting the HMLER90hi cells with clodronate liposomes 14 . Nude mice were used in this and subsequent experiments instead of NOD-SCID hosts because of the documented defect in macrophage activation in the latter. Strikingly, tumour initiation was almost completely blocked by macrophage depletion, suggesting that endogenous macrophages in the tumour microenvironment are critical for the survival and proliferation of implanted CSCs (Fig. 4a) . To examine the opposite effect, we co-injected HMLER90hi cells with either primary human monocytes or mouse TAMs isolated from HMLER90hi xenografts ( Supplementary Fig. 4a ). The admixture of either human monocytes or mouse TAMs resulted in higher tumour incidence and size, indicating that they promoted tumour outgrowth by CSCs (Fig. 4b) .
The TAMs within tumours arising from CSCs showed low expression of Nos2 (M1 polarization), and high expression of Arg1, MRC1, FIZZ1 and VEGF (M2 polarization 30 ), which resembled the expression patterns of tumour-promoting TAMs (ref. 31 ) isolated from mammary tumours in the MMTV-PyMT mice ( Supplementary  Fig. 4b ). Moreover, when analysing the CD68 + TAMs from the patient samples described above, we found that these cells were predominantly CD163 + HLADR −/dim ( Supplementary Fig. 4c ), indicative of an M2, tumour-promoting phenotype 32 . Various types of tumour-infiltrating immune cells, including lymphocytes, have been shown to modulate the function of TAMs (ref. 33) . Therefore, we examined the effect of TAMs on CSC activities in immunocompetent mice. The MMTV-PyMT mice are known to develop mammary tumours that harbour CD90 + CSCs, which efficiently metastasize to the lungs when injected intravenously 10 . We sorted freshly isolated mouse mammary carcinoma cells based on CD90 expression from the MMTV-PyMT-driven metastatic tumours and then injected the resulting CD90 + and CD90 − populations, with or without TAMs, orthotopically into wild-type syngeneic hosts. All groups developed tumours of similar weight ( Supplementary  Fig. 4d) ; lymphocyte infiltration was readily detected within the tumours, resembling spontaneously arising MMTV-PyMT tumours ( Supplementary Fig. 4e ,f). However, tumours that arose from CD90 − non-CSCs (with or without co-injected TAMs) were largely necrotic and contained cysts filled with fluid ( Supplementary Fig. 4g ,h), with low numbers of proliferating cells ( Supplementary Fig. 4i ,j) and no metastasis in the lungs (Fig. 4c,d ). CD90
+ CSCs injected on their own resulted in tumours with less necrosis and more proliferating cells but yielded very few lung metastases. In contrast, the CD90 + CSCs with co-injected TAMs resulted in tumours that contained little necrosis, were more proliferative, and metastasized to lung with a 22-fold higher CSCs were injected alone (e) or with admixed TAMs (f) at limiting dilution orthotopically (n = 10 mice per group). Tumour incidence was determined by weekly palpation, and tumours were collected and weighed at 50 days post injection (g). Data were pooled from 2 independent experiments, each assessing 5 mice per group. (h) CD90 lo non-CSCs were injected alone or with admixed TAMs orthotopically but no tumour formed. Data were pooled from 2 independent experiments, each assessing 5 mice per group. (i,j) HMLER90hi cells injected alone or together with TAMs were allowed to grow in the mammary fat pads of NOD-SCID mice for 3 weeks; the tumour cells were then collected and seeded for tumorsphere forming assay (i presents data from 4 technical replicates) or injected as secondary tumour transplants into recipient NOD-SCID mice (j) to measure tumour-initiating capability. Data shown are from one experiment out of two biological replicates; source data are provided in Supplementary Table 7 (i,j). Error bars indicate s.e.m. NS, not significant; * P < 0.05; * * * P < 0.001; * * * * P < 0.0001 (Student's t-test for a,b,g and one-way ANOVA for c).
efficiency than CD90
+ CSCs injected alone. These data supported the notion that the co-injected macrophages promoted more robust primary tumour growth and enhanced the metastatic CSC activity of the CD90 + carcinoma cells in the context of an intact immune system. We noted that both the CD90 + and CD90 − MMTV-PyMT carcinoma cells initiated primary tumours efficiently. This is probably due to the fact that the tumour cells were isolated from spontaneously arising MMTV-PyMT tumours at the stage of metastatic dissemination, when most of the carcinoma cells had evolved to be rapidly proliferating following weeks of robust tumour growth.
Effects of admixed macrophages on tumour initiation
We reasoned that the direct contact of macrophages with the CSCs might allow the TAMs to provide signals important for the maintenance of their CSC state. To determine whether TAMs enhance tumour initiation rates and thus enrich for CSCs we performed tumour xenograft experiments by implanting the carcinoma cells in limiting dilutions. Co-injecting macrophages with the CD90 hi CSCs resulted in earlier tumour onset (Fig. 4e ,f) as well as higher tumour incidence and burden compared with CSCs injected alone (Fig. 4g) ; in contrast, CD90 lo non-CSCs did not initiate tumours either with or without admixed TAMs (Fig. 4h) .
To measure more precisely the frequency of CSCs from the tumours with admixed TAMs, we injected CSCs in the presence or absence of TAMs into mouse mammary fat pads and collected the tumours three weeks later when they were no larger than 0.2 g ( Supplementary  Fig. 4k ). The cancer cells from the TAMs+CSCs group formed more tumorspheres and initiated tumours with a 17-fold higher efficiency in a secondary transplantation experiment than those from the CSCsonly injected tumours (Fig. 4i,j) . Taken together, these data confirmed directly the ability of TAMs to boost the representation of CSCs in these carcinoma cell populations, ostensibly by enabling CSCs to maintain their residence in the stem cell state.
Monocyte/macrophage-stimulated cytokine production in the stem-like cells
We then sought to dissect the molecular mechanism for the interaction between CSCs and monocytes/macrophages. As cytokines are known to mediate the interactions between cancer cells and TAMs (ref. 29) , we measured the expression of various cytokine mRNAs in both HMLER90hi cells and THP1 monocytes that had been separated by fluorescence-activated cell sorting (FACS) after 3 h of co-culture ( Supplementary Fig. 5a ). Widespread changes in cytokine expression were already apparent in both cell populations within this time period (Supplementary Tables 2 and 3 ). Strikingly, we observed rapid and robust induction of mRNAs encoding IL-6, IL-8 and GM-CSF in the HMLER90hi cells, whose levels far exceeded the cytokines produced by the co-cultured monocytes.
The mRNA levels of IL-6, IL-8 and GM-CSF rose abruptly following monocyte co-culture and persisted for at least 6 h (Fig. 5a ). HMLER90lo cells, used as controls, showed only a modest and transient increase in these cytokines in response to monocyte co-culture. Importantly, the induction of these cytokines in the HMLER90hi cells was completely blocked when they were separated from the monocytes by a cell-impermeable insert, indicating that the observed signalling between the two cell types required direct cell-cell contact, that is, juxtracrine signalling. Virtually no cytokines were detected in the conditioned medium by enzyme-linked immunesorbent assay (ELISA) from mock-treated HMLER90hi cells in contrast with the robust increases of cytokine levels after 4 h of coculture (Fig. 5b) ; membrane-separated indirect co-cultures yielded only marginal if any increases in the three cytokines. Knockdown of CD90 by shRNA resulted in a twofold to threefold reduction in cytokine mRNA induction in the HMLER90hi cells (Fig. 5c) , probably due to the reduced number of monocytes adhering to these cells.
We also noted that the induction of IL-6, IL-8 and GM-CSF in the stem-like cells did not require the actions of H-RasV12, because the CD90 hi CD24 − cells from the non-transformed HMLE-Twist and HMLE-Slug stem-like cells also responded to monocyte co-culture by producing these cytokines, whereas the parental epithelial HMLE cells, used here as controls, showed only a marginal upregulation of the cytokines (Fig. 5c ). In addition, cytokine induction in the CD90 hi cells was also observed when primary mouse macrophages or primary human monocytes were used instead of THP1 monocytes (Fig. 5d,e) , which indicated that the above observations applied to a variety of monocytes/macrophages, and that the signalling between mouse macrophages and the human HMLE-derived CD90 hi CD24 − cells was not compromised by inter-species signalling incompatibilities.
IL-6 and IL-8 have been shown to induce and maintain the CSC state in autocrine and paracrine fashions 9, 34, 35 . In HMLER90hi cells, individual knockdown of IL-6 or IL-8 led to cessation of cell proliferation in culture, whereas the proliferation of epithelial HMLERas cells was unaffected by the knockdowns (Supplementary Fig. 5b,c) . In addition, IL-8 overexpression or treatment with recombinant IL-6 and/or IL-8 resulted in more efficient tumorsphere formation by the HMLER90hi cells, indicating that IL-6 and IL-8 can indeed act on the HMLER90hi cells to promote the expansion of CSCs ( Supplementary  Fig. 5d-f ). GM-CSF is known to promote the differentiation of TAMs into tumour-supporting phenotypes 12, 33 , and may act in a paracrine fashion to perpetuate the CSC-TAM interaction. The three cytokines therefore may further reinforce and sustain the stem cell state of the HMLER90hi CSCs.
Role of EphA4 in mediating signalling activation in the stem-like cells
We undertook to determine the molecular mechanisms that were responsible for the marked induction of cytokines following exposure of normal and neoplastic MaSCs to monocytes. CD90 lacks an intracellular domain and hence is poorly equipped to transduce signals across the plasma membrane 18 . As an alternative, we considered the well-documented CSF1-EGF paracrine loop between TAMs and breast cancer cells 31, 36 ; however, the expression of EGFR is strongly downregulated during passage through an EMT (refs 6,37,38) , rendering it unlikely to mediate the response of CSCs to TAMs.
We therefore searched for other cell-surface receptor candidates that could mediate the juxtacrine signalling from our proteomics analysis. Three receptor tyrosine kinases (RTKs)-ROR1 (a pseudokinase 39 ), PDGFRβ and EphA4-were strongly upregulated in the stem-like cells (Fig. 1a, Supplementary Table 1 and Supplementary Fig. 6a ); among these, only EphA4 is known to mediate contact-dependent signalling following binding with plasma-membrane-associated Ephrin ligands displayed on closely apposed cells 40 . We noted that whereas peptides shared by several Eph RTKs showed little change in levels, MS analysis of the peptides unique to EphA4 revealed its upregulation by over 20-fold following passage through an EMT (Methods).
We measured the activation of the RTKs on contact with monocytes by immunoblotting after removal of monocytes following co-culture ( Supplementary Fig. 6b ). Only EphA4 showed a robust increase in activation in the stem-like HMLER90hi cells and HMLE-Twist cells following direct monocyte co-culture (Fig. 6a,b and Supplementary  Fig. 6c) .
A KYL peptide has been shown to specifically inhibit EphA4 activation 41 . Treatment of co-cultures with the KYL peptide, but not the KYL-P7A control peptide 41 , blocked 90% of EphA4 phosphorylation in the HMLER90hi cells and significantly reduced the secretion of the three cytokines (Fig. 6c,d) . Consistently, shRNA knockdown of EphA4 in the HMLER90hi cells hindered cytokine mRNA induction by monocytes ( Supplementary Fig. 6d,e) . Taken together, these data demonstrated the involvement of EphA4 in monocyte-stimulated cytokine production in the CSCs. This was further supported by our observation that knockdown of EphA4 in the CSCs led to a fourfold reduction in the size of resulting tumours (Fig. 6e) .
As EphA4 activation requires direct engagement of its ligand displayed on the surface of monocytes, it is likely that CD90 physically anchors the monocytes to the HMLER90hi cells, thereby providing the physical association that is essential for the Ephrin ligandreceptor juxtacrine signalling. As expected, we observed that EphA4 phosphorylation in the CD90 knockdown cells was 40% lower than in the control cells when co-cultured with monocytes ( Supplementary  Fig. 6f ).
The EphA4 receptor can promiscuously bind to both types of human Ephrin ligand, including five glycosylphosphatidylinositol (GPI)-linked ephrin-A ligands and three transmembrane ephrin-B ligands 40 . Pretreatment of the monocytes with recombinant PI-specific PLC before co-culture resulted in decreased phosphorylation of the EphA4 receptor, indicating that the ephrin ligand(s) displayed by the Supplementary Fig. 7 .
monocytes belong to the GPI-anchored type A family ( Supplementary  Fig. 6g) . Consistently, the EphA2 receptor, which recognizes only ephrin-A ligands, was also activated in the CSCs on co-culture with monocytes. Given that EphA4 can bind all five ephrin-A ligands, we did not pursue the precise identity of its cognate ephrin-A ligand(s) displayed by the monocytes/macrophages. (Fig. 6a,b) . Activation of these proteins was greatly reduced when treated with the KYL peptide (Fig. 6c) .
Intracellular signalling
PKCδ is known to mediate degradation of IκB, allowing NF-κB to translocate into the nucleus 45 , which can then drive the transcription of various genes including IL-6, IL-8 and GM-CSF (refs 46-48) . Indeed, knockdown of PLCγ1 and PKCδ in the HMLER90hi cells resulted in a 2-10-fold reduction in the induction of the three cytokine mRNAs (Fig. 6f,g ). Consistently, phosphorylation of PLCγ1 could be readily detected in the tumour cells adjacent to TAMs in the HMLER90hi tumour xenografts (Fig. 6h) .
NF-κB activation in the CSC-like HMLER90hi cells
We also undertook to examine in more detail the involvement of the PKCδ-stimulated NF-κB signalling in the HMLER90hi cells. The expression of an NF-κB super-repressor (IκBα S32A/S36A; ref. 49) in the HMLER90hi cells blocked the cytokine mRNA induction in these cells following co-culture with monocytes or macrophages (Figs 7a and 5d,e) . Secretion of the cytokines from the co-cultured cells was also reduced by more than tenfold when the NF-κB superrepressor was expressed in the HMLER90hi cells (Fig. 7b) , which further demonstrated that the three cytokines were largely secreted by the HMLER90hi cells and not by the monocytes. Consistently, we observed a time-dependent nuclear accumulation of the NF-κB subunits p65 and, more strikingly, p50, in the CD90 hi cells following co-culture with the monocytes (Fig. 7c) .
More importantly, human monocytes or TAMs failed to promote tumour initiation or growth from the NF-κB super-repressorexpressing HMLER90hi cells, indicating that NF-κB activation and cytokine induction in the CSCs are functionally essential for the tumour-promoting effects of the TAMs (Fig. 7d) . In addition, the tumours from co-injected CSCs and TAMs had substantially fewer apoptotic cells, consistent with the well-known roles of the NF-κB pathway and Src in conferring resistance to apoptosis (Fig. 7e) .
The Twist EMT-TF has been shown to mediate IL8 transcription in cooperation with the RelA NF-κB subunit 50 . Indeed, we detected the association of the p50 NF-κB subunit with the endogenous Twist protein in the HMLER90hi cells by co-immunoprecipitation (Fig. 7f) . Using chromatin immunoprecipitation (ChIP), we found that Twist was moderately enriched close to the transcription start site of IL6, IL8
and CSF2 (encoding GM-SCF) in the absence of monocytes, whereas no binding of p50 was observed. Following monocyte co-culture, we detected significant increases in the binding of both Twist and p50 to the same promoter regions (Fig. 7g) . Hence, it seems that when stimulated by monocytes/macrophages, the EphA4 protein on the HMLER90hi cells activates the NF-κB p50 subunit, which then enters the nucleus and cooperates with Twist to further increase its binding to the cytokine promoters, contributing to the robust cytokine induction in the stem-like cells (Fig. 7h) .
DISCUSSION
The EMT program is an important component of carcinoma progression by conferring on the cancer cells invasiveness and by enriching for stem cell properties [2] [3] [4] . Here, we have shown that EMTinduced stem-like human mammary epithelial cells (HMECs) interact with and respond to monocytes and macrophages far more robustly than do differentiated, non-stem-like HMECs. In the context of cancer, these cell-cell contact-dependent interactions provide evidence of a physical CSC niche supported by the TAMs. Such direct contact could be visualized in xenograft tumours as well as patient-derived breast tumour sections. Furthermore, we delineated the receptors and signalling pathways mediating such interactions in the CSCs, which were confirmed using tumour cell transplantation models. The observed responses of the CSCs seem to sustain their residence in the stem cell state by self-reinforcing, positive-feedback loops ( Supplementary Fig. 6h) .
Intriguingly, co-injection of CD90 + MMTV-PyMT tumour cells with TAMs into the mammary fat pads of wild-type syngeneic mice resulted in more efficient lung metastases than CD90 + CSCs injected on their own. In addition to enhancing initial survival and proliferation of the CSCs, we suspect that the cohort of cytokines secreted in response to the TAM-CSC interaction facilitated the induction of tumour-supportive stroma, allowing tumour progression to metastatic carcinoma. In contrast, when CD90 + CSCs were injected alone into wild-type syngeneic hosts, in the absence of various tumour-promoting and immune-suppressing cytokines produced by the interacting CSCs and TAMs, the subsequently recruited immune cells may have adopted tumour-suppressive phenotypes 33 . The effects of the immune cells on the CSC activities await further investigation.
During embryonic development, macrophages derive from the yolk sac and fetal liver before haematopoiesis, arising as the earliest cells of the haematopoietic lineage 12 . Among other functions, these tissue macrophages probably participate in embryonic organ development by providing effectors necessary for the formation and function of various tissue stem cell niches. It has been reported that mouse MaSC function requires the continuing presence of macrophages in the developing mammary gland 14 . This suggests that components of the heterotypic interactions between normal MaSCs and monocytes/macrophages are recapitulated in the carcinoma stem cells.
More broadly, the observed physical interactions between CSCs and TAMs may quite possibly operate in other carcinoma types. Increased expression of CD90 has been reported in CSCs of liver cancer, gastric cancer, colon cancer and glioma [51] [52] [53] [54] . EphA4 overexpression has been observed in gastric cancer 55 and liver cancer metastasis 56 . Additional Ephrin receptor family members EphA2 and EphB2 have been shown Table 7 . (h) A depiction of the signalling transduction pathway in a CSC when stimulated by a monocyte/macrophage. Uncropped images of blots are shown in Supplementary Fig. 7 .
to be upregulated in glioblastoma tumour-propagating cells and in colon CSCs (refs 11,57 Co-culture assays. The HMLE-derived cells were seeded into culture dishes at 30% confluency, and grown into a ∼70% confluent monolayer 18 h later. The THP1 monocytes were pelleted by centrifugation at 300g , resuspended in the MEGM medium at 1 million cells ml −1 , and laid on top of the monolayer cells (cell number of monocytes/monolayer cells = 3:2). The non-adherent monocytes were gently rinsed away after 1 h by two washes with PBS, and the cells in the culture were replenished with fresh MEGM medium. Cells were trypsinized at indicated time points and resuspended in 2% IFS/PBS for fluorescence-activated cell sorting (FACS) sorting. For conditioned medium collection, fresh MEGM medium was added to the coculture (without removing existing medium) after 1 h, and the conditioned medium was collected after filtering through a 0.2 µm Acrodisc syringe filter (Pall Life Science no. PN4192). For the peptide inhibitor experiments, the monolayer HMLER90hi cells were treated with the indicated peptide or dimethylsulphoxide for 40 min before and during the monocyte co-culture.
FACS and flow cytometry. Cells were prepared according to standard protocols and suspended in 2% IFS/PBS. DAPI (Life Technologies) was used to exclude dead cells. Cells were sorted on BD FACSAria SORP and analysed on BD LSRII, using BD FACSDiva Software (BD Biosciences). Antibodies used were anti-CD90-APC (BD Biosciences no. 559869), anti-CD24-PE (BD Biosciences no. 555428).
Mammosphere/tumorsphere culture. Mammosphere/tumorsphere culture was performed as previously described 22 . The number of cells seeded per well was labelled for each graph in the figures. Sphere numbers were counted between days 8 to 12.
RNA preparation and qRT-PCR analysis. Total RNA was isolated using the RNeasy Plus Mini kit (Qiagen) and reverse transcription was performed with the High Capacity RNA-to-cDNA Kit (Applied Biosystem), both according to the manufacturer's protocol. A cDNA sample prepared from 1 µg total RNA was used for each PCR. The PCR reactions using SYBR Green Mix I (Roche Diagnostics), data collection and data analysis were performed on the LightCycler 480 System (Roche Diagnostics). The thermal cycling parameters for the PCR were as follows: 95 • C for 5 min, followed by 45 cycles of 95 • C for 10 sec, 49 • C for 7 sec, and 72 • C for 25 sec. The relative mRNA quantity was normalized against the relative quantity of GAPDH mRNA in the same sample. Primers used are indicated in Supplementary Table 4 .
Enzyme-linked immune-sorbent assay. Concentrations of cytokines IL-6, IL-8 and GM-CSF in conditioned media were detected by ELISA kits from Ray Biotech (IL-6 and GM-CSF) and EBiosciences (IL-8) according to the manufacturers' protocols. The absorbance was measured on a Multiskan EX (Thermo Electron Corporation).
Cell proliferation assay. Cells were seeded in 96-well assay plates (Corning no. 3903) at 1000 cells per well, and the culture medium was replenished every 2 days. Cell proliferation was measured at the indicated days after seeding with WST1 reagent (Roche 11644807001) according to the manufacturer's protocol.
Isolation of primary mouse macrophages and human monocytes.
To isolate mouse intraperitoneal-exude macrophages, mice were injected with 2% v/v Bio-Gel P-100 (Bio-Rad no. 150-4174) intraperitoneally (1 ml per mouse). Three days later, the mice were euthanized; RPMI medium was injected intraperitoneally and then retrieved. The cells were then treated with Red Blood Cell Lysing Buffer (SigmaAldrich) and washed with PBS. The purity of the intraperitoneal-exude macrophages was analysed by flow cytometry after staining with anti-CD11b-PE (BD Biosciences no. 557397), anti-Ly-6G-AlexaFlour700 (BD Biosciences no. 561236) and anti-F4/80-PE-Cy7 (EBiosciences 25-4801-82). Mouse tumour-associated macrophages (TAMs) were isolated from dissociated mouse tumours previously grown from the HMLE-Ras CD90 hi cells. Human monocytes were isolated from human peripheral blood mononuclear cells from healthy donors. Mouse TAMs and human monocytes were purified by magnetic activated cell sorting with anti-F4/80-PE-Cy7 followed by anti-PE microbeads (Miltenyi Biotec), and human CD14 microbeads (Miltenyi Biotec), according to the manufacturer's protocol. The purity of mouse TAMs was directly analysed by flow cytometry after magnetic activated cell sorting. The purity of human monocytes was analysed by flow cytometry after staining with anti-CD14-PE-Cy7 (25-0149-71), anti CD11b-APC (17-0118-71) antibodies (both from EBiosciences).
Creation of stable cell lines. GFP-labelled HMLE, HMLE-Twist and HMLE-
Slug cell lines were made by retroviral transduction using the pWZL-blast-GFP expression vector 59 . The HMLE-Ras cell line (HMLER) was made by retroviral transduction with the pMSCV-HRasV12-IRES-GFP expression vector 60 . The tdTomato fluorescent protein-labelled THP1 monocytes (THP1-RFP) were made by lentiviral transduction using the pLV-tdTomato expression vector 61 . NF-κB superrepressor-expressing HMLER90hi cells were made by retroviral transduction using the pBabe-puro-IκBα-S32A/S36A expression vector (Addgene plasmid 12332; ref. 62). Short hairpin RNAs (shRNAs) targeting the mRNAs encoding CD90 (Thy1), EphA4, PLCγ1, PKCδ, IL-6, IL-8 and GM-CSF were expressed from pLKO.1-puro (Open Biosystems); the target sequences of these shRNA hairpins are indicated in Supplementary Table 5 . All stable cell lines were generated by retroviral infection using HEK293T cells, as previously described 63 , and followed by selection with puromycin (2 µg ml −1 ) or by cell sorting.
Western blotting. Phospho-and total-protein lysates were prepared with urea lysis buffer (9 M urea, 20 mM HEPES, pH 8.0), with freshly added phosphatase inhibitors (1 mM sodium orthovanadate, 5 mM sodium pyrophosphate and 1 mM β-glycerol-phosphate). For the separation of monocytes from the monolayer HMLEderived cells, phosphatase inhibitors (1 mM sodium orthovanadate, 5 mM sodium pyrophosphate) were added to the culture medium before collection and the monocytes were repeatedly flushed off with the medium; the monolayer cells were rinsed with cold PBS and immediately lysed on the culture dish. The monocytes were then pelleted by centrifugation at 300g for 5 min and then lysed. For  Fig. 7c , nuclear and cytoplasmic extracts were prepared using the NE-PER kit (Pierce). Concentrations were determined using the Dc protein assay (Bio-Rad). For Supplementary Fig. 6a , total protein was extracted with RIPA lysis buffer. Protein lysates were resolved on a 4%-12% Bis-Tris gel, transferred to PVDF membranes, probed with primary antibodies overnight at 4 • C and then with HRPlinked secondary antibodies (Cell Signaling Technology, CST) and visualized with ECL reagents (Thermo Scientific). The dilution, clone and catalogue numbers of the antibodies used are listed in Supplementary Table 6 .
Co-immunoprecipitation and chromatin immunoprecipitation assay.
Co-immunoprecipitation of Twist and NF-κB p50 was performed using the HMLER90hi cells with an endogenous high level of Twist. The monolayer cells were rinsed with cold PBS and lysed in the IP buffer (20 mM Tris, pH 7.5, 200 mM NaCl, 5 mM MgCl 2 , 0.1% NP40-substitute, 10% glycerol, with 1 mM dithiothreitol), 0.5 mM phenylmethyl sulphonyl fluoride (PMSF) and 1× protease inhibitor (Roche) freshly added before lysis). Cell lysates were incubated at 4 • C with the anti-Twist antibody (Abcam no. ab50887) or control IgG (CST, no. 5415) overnight (Supplementary Table 6 ). The protein-antibody mixture was then precipitated with the protein G magnetic beads (Invitrogen) according to the manufacturer's protocols. NF-κB p50 was then detected with the anti-p105/p50 antibody (CST, no. 3035) by western blot. The chromatin immunoprecipitation assay was performed as previously described with the same antibodies 64 . The dilution, clone and catalogue numbers of the antibodies used are listed in Supplementary Table 6 . The PCR primers used for confirming the protein bindings were: promoter probe for IL6: 5 -TTCCAATCAGCCCCACCCG-3 /5 -GCTGGCAGTTCCAGGGCTAAGG-3 ; control probe for IL6: 5 -TCTGG AGACTGGAGGGACAACC-3 /5 -GGACGCAGGCACGGCTCTA-3 ; promoter probe for IL8: 5 -CATCAGTTGCAAATCGTGGAAT-3 /5 -GAGTGCTCCGGT GGCTTTTTAT-3 ; control probe for IL8: 5 -AAGAGCATGAAGCAACAGTGGC-3 /5 -AATAGGAGGGCTTCAATAGAGG-3 ; promoter probe for CSF2: 5 -AAGT TCTCTGGAGGATGTGGCTGC-3 /5 -CCATCTCAGCAGCAGTGTCTCTAC-3 ; control probe for CSF2: 5 -TGGGGGATGCTGGGGTTATGTA-3 /5 -TAGCC CCCAGAAGACACCAGGAG-3 .
Phosphatidylinositol-specific phospholipase C protein (PI-PLC) treatment.
THP1 monocytes were resuspended in PBS at 2 million cells ml −1 , and incubated with 1 µ ml −1 PI-PLC (Invitrogen no. P-6466) at 37 • C for 1 h. Monocytes were then washed with PBS once and resuspended in MEGM medium for co-culture experiments.
Animal experiments. All research involving animals complied with protocols approved by the MIT Committee on Animal Care. The number of cells and the time for tumour growth are indicated in the figure legends. To measure tumour-initiating cell/CSC frequency (Fig. 2a,g, 4j and 6e and Supplementary  Fig. 2d,f) , serial dilutions of cancer cell suspensions in 25 µl of a 1:1 MEGM and Matrigel (BD Biosciences) mixture were injected into the fourth mammary fat pads of 2-3-month-old female NOD-SCID mice. CSC frequencies of the samples were determined using the ELDA webtool 65 . In TAMs+CSCs co-injection experiments (including the CSCs-only control groups; Figs 4b-h and 7d), the amount of Matrigel was reduced by sixfold to minimize any effects of growth factors from the Matrigel. Thus, the cells were suspended in 10 µl of a 4:1 MEGM and Matrigel mixture and injected into the fourth mammary fat pads of twomonth-old female Nude mice. For the MMTV-PyMT tumour cell transplantation experiment ( Fig. 4c,d; Supplementary Fig. 4d-j) , naturally arising MMTV-PyMT tumours from 10-to 14-week-old females were collected (with their lungs being checked for visible macro-metastases to gauge the metastatic capabilities of the tumour cells). The tumour cells were dissociated into single-cell suspension, subjected to negative selection by CD45, CD31 and Ter-119 microbeads (Miltenyi) and then sorted for CD90 expression. Separate MMTV-PyMT tumours were dissociated for the isolation of TAMs. Tumour cells (3 × 10 5 ) were injected with or without 1.5 × 10 5 TAMs in a volume of 10 µl including 2 µl Matrigel into the fourth mammary fat pads of 2-month-old female wild-type Fvb mice. Tumours and lungs were collected after two months. Tumour weight was measured after draining of fluid in the cyst-containing tumours. The investigator was not blinded to the group allocation for the assessment of outcome. Mice were randomly allocated to each group by an independent person; however, no particular method of randomization was used. No statistical method was used to predetermine sample size.
Patient samples. The tissues used in this study were collected under a University of Pittsburgh Internal Review Board (UPCI 04-162). All patients consented before surgery or any other clinically indicated procedure. All specimens are deidentified by an honest broker system and distributed for research. Tissues used for immunohistology were processed within 2 h of surgery.
Immunohistostaining
Mouse tumours. Formalin-fixed paraffin-embedded xenograft tumour tissue slides were stained with primary antibodies mouse anti-α-SMA (Sigma), rat anti-F4/80 (Invitrogen, MF48000), rabbit anti-PLCγ1 (pY783) (Abcam, no. ab53125), rabbit anti-cleaved caspase 3 (CST no. 9664) and mouse anti-Ki67 (BD Biosciences no. 550609), and the secondary antibodies used were goat anti-mouse Alexa594, goat anti-rat Alexa488, and donkey anti-rabbit Alexa 555 (Supplementary Table 6 ). Nuclear staining was performed with DAPI (Invitrogen). Slides were mounted in Prolong Gold anti-fade reagent (Invitrogen). Immunofluorescent staining was observed and photographed using a Nikon Eclipse E800 upright fluorescence microscope.
Patient tumour tissues.
All tissues BrCA022T, BrCA032T, BrCA041T (invasive ductal carcinomas, ER+/PR+) and BrCA042T (invasive ductal carcinoma, ER−/PR−) were formalin-fixed and paraffin-embedded. Antigen retrieval of tissue sections was performed at 125 • C for 20 min in pH 6.0-EDTA buffer (Dako); these were washed and blocked with blocking solution (PBS, 5% goat serum, 0.05% Tween 20) to reduce nonspecific antibody binding. All wash steps were performed with Dako wash buffer. Immunofluorescence staining was performed using the following primary antibodies overnight at 4 • C: monoclonal rabbit anti-human CD90 (Abcam, catalogue no. ab133350), mouse anti-human CD68 (Dako catalogue no. M0876). Negative control primary antibodies were purchased from Dako (N1698 and N1699). After washing, biotinylated secondary goat antirabbit biotin (Dako catalogue no. E0432), goat anti-mouse Alexa488 antibody (CD90/CD68 double staining, Invitrogen catalogue no. A11001) or goat antimouse Cy5 antibody (CD90/CD68/CTK triple staining; Abcam catalogue no. ab97037) was applied for 1 h at room temperature, followed by incubation with streptavidin-Cy3 (Sigma, catalogue no. 6402) for 30 min at room temperature. For triple staining mouse anti-CTK-FITC [AE1/AE3] (eBioscience, catalogue no. 53-9003-80) was incubated for 1 h at room temperature. For detailed information on the antibodies used see Supplementary Table 6 . Final nuclear staining was performed with DAPI (Invitrogen, catalogue no. D1306). Slides were mounted in Prolong Gold anti-fade reagent (Invitrogen, catalogue no. P36934). Immunofluorescent staining was observed and photographed using a Nikon 90i motorized upright epi-fluorescence microscope using a ×20 objective. Whole sections were photographed as a composite of individual 'tiles' captured and joined using the NIS-Elements software. Individual CD90 + /CD68 + cellular doublets were identified from the ×20 whole-section tiled images. Confocal images of the doublets were obtained using an Olympus Fluoview 1000 microscope (version 2.16 software) and a Plan Apo N ×60 1.42 N.A. objective, ×4 zoom, and 0.45 µm sections (number varied depending on cells imaged: [13] [14] [15] [16] [17] . Stacks were processed using MetaMorph (version 7.7) and autocontrast was applied consistently to all wavelengths.
Statistical analysis. Data are presented as mean ± s.e.m. Student's t-test (unpaired) was used to compare two groups (P < 0.05 being considered significant). HolmSidak's multiple comparisons test was performed when one-way ANOVA was used to compare between more than two groups. Sample sizes were indicated in each corresponding figure legends. Membrane protein fractionation. Membrane protein isolation is described in Supplementary Fig. 1b,c . The buffers used were as follows: lysis buffer: 10 mM Tris, pH 7.5, 5 mM MgCl 2 , 0.5 mM PMSF, and 0.5% PMSF and 1% protease inhibitors (Sigma) fresh before use; sucrose buffer: 10 mM Tris, pH 7.5, 1.25 M sucrose (molecular mass 342.3 Da). Membrane proteins were pelleted in an ultraclear tube (Beckman no. 344057) in a Beckman ultracentrifuge (model no. L8-M) with rotor SW50.1.
Solubilization, digestion and peptide fractionation by off-gel electrophoresis.
Membrane protein pellets (1 mg) were solubilized in urea and disulphide bonds were reduced and alkylated; then proteins were deglycosylated with PNGaseF and digested with Lys-C, and trypsin. Solutions that began cloudy on initial reconstitution were clear after overnight digestion. Samples (∼50 µg) of peptide digest were separated by off-gel electrophoresis according to their isoelectric point into 11 fractions using an Agilent 3100 OFFGEL Fractionator (Agilent Technologies) and 13 cm Immobiline Drystrips pH 3-10 (GE Healthcare BioSciences AB). Experimental details have been previously described 67 .
Mass spectrometry. Peptide off-gel electrophoresis fractions were analysed with an automated nano LC-MS/MS system, consisting of an Agilent 1100 nano-LC system (Agilent Technologies) coupled to either an LTQ-Orbitrap or an LTQ Orbitrap XL Fourier transform mass spectrometer (Thermo Fisher Scientific) equipped with a nanoflow ionization source (James A. Hill Instrument Services). Peptides were eluted from a 10 cm column (Picofrit 75 µm ID, New Objectives) packed in-house with ReproSil-Pur C18-AQ 3 µm reversed-phase resin (Dr. Maisch , Ammerbuch Germany) using either a 120 or 133 min gradient at a flow rate of 200 nl min −1 to yield ∼20 s peak widths as previously described 67 . Data-dependent LC-MS/MS spectra were acquired in ∼3 s cycles; each cycle was of the following form: one full Orbitrap MS scan at 60,000 resolution followed by 8 MS/MS scans in the ion trap on the most abundant precursor ions using an isolation width of 3 m/z. Dynamic exclusion was enabled with a mass width of +/−25 ppm, a repeat count of 1 and an exclusion duration of 45 sec. Charge-state screening was enabled along with monoisotopic precursor selection and non-peptide mono-isotopic recognition to prevent triggering of MS/MS on precursor ions with unassigned charge or a charge state of 1. Normalized collision energy was set to 30 with an activation Q of 0.25 and activation time of 30 ms. Two biological replicates were performed.
Protein identification and quantification. All MS data were interpreted using the Spectrum Mill software package v4.1 beta (co-developed by us with Agilent Technologies). Similar MS/MS spectra acquired on the same precursor m/z within +/−45 s were merged; MS/MS spectra with precursor charge >4 and poor-quality MS/MS spectra, which failed the quality filter by not having a sequence tag length >0 (that is, minimum of two masses separated by the in-chain mass of an amino acid), were excluded from searching. MS/MS spectra were searched against a UniProt database containing 78,369 human sequences (including isoforms and excluding fragments) downloaded from the UniProt web site on 30 June 2010, along with 73 common laboratory contaminant proteins appended. Search parameters included: ESI linear ion-trap scoring parameters, trypsin enzyme specificity with cleavage at K-P or R-P allowed, a maximum of 4 missed cleavages, 35% minimum matched peak intensity, +/−20 ppm precursor mass tolerance, +/−0.7 Da product mass tolerance, and fixed/mix modifications that included carbamidomethylation of cysteines and either unlabelled Arg, Lys or SILAClabelled Arg 10, Lys 8. Allowed variable modifications were oxidized methionine, deamidation of asparagine, pyro-glutamic acid modification at amino-terminal glutamine, and pyro-carbamidomethyl modification at N-terminal cysteine with a precursor MH+ shift range of −18-64 Da.
Identities interpreted for individual spectra were automatically designated as confidently assigned using the Spectrum Mill autovalidation module to apply targetdecoy-based false-discovery rate (FDR) scoring threshold criteria using a two-step auto threshold strategy at the spectral and protein levels. First, peptide mode was set to allow automatic variable range precursor mass filtering with score thresholds optimized to yield a spectral-level FDR of 1.6% for each precursor charge state in each LC-MS/MS run. Second, protein mode was applied to further filter all of the peptide-level validated spectra combined from the 22 LC-MS/MS runs from both replicates of an experiment using a minimum protein score of 20 and a maximum protein-level FDR of zero. As the maximum peptide score is 25, the protein level step filters the results so that each identified protein is comprised of multiple peptides unless a single excellent scoring peptide was the sole match. The above criteria yielded target-decoy-based FDR estimates for each sample replicate of 0.9-1.0% at the peptide-spectrum match level and 1.3-1.5% at the distinct peptide level.
For scores calculated at the protein level and reporting of identified proteins, redundancy is addressed as follows. The protein score is the sum of the scores of distinct peptides. A distinct peptide is the single highest scoring instance of a peptide identified by an MS/MS spectrum. MS/MS spectra for a particular peptide may have been recorded multiple times (that is, both heavy and light SILAC labels, different precursor charge states, isolated from adjacent off-gel electrophoresis fractions, modified by deamidation at asparagine or oxidation of methionine) but are still counted as a single distinct peptide. When a peptide sequence >8 residues long is contained in multiple protein entries in the sequence database, the proteins are grouped together and the highest scoring one and its accession number are reported. In some cases when the protein sequences are grouped in this manner there are distinct peptides that uniquely represent a lower scoring member of the group (isoforms, family members). Each of these instances spawns a subgroup and multiple subgroups are reported and counted towards the total number of proteins with each given related protein.subgroup numbers (for example, the ephrin receptor tyrosine kinase family shares sufficient sequence homology that the observed shared and distinct peptides resulted in one protein group with 4 subgroups corresponding to EPHA2, EPHA4, EPHB2 and EPHB4 and are listed as subgroup members 214.1 to 214.4 in Supplementary Table 1) . GO annotations were then used to categorize all of the identified protein subgroups as being plasma membrane associated, extracellular matrix derived, and/or tyrosine kinases. EphA4 is complicated by the fact that there is over 50% sequence identity among the Ephrin family members with distinct peptides detected for EphA2, A4, B2, B4. In each replicate a single distinct A4 tryptic peptide was observed, different ones each time, and both showed >20-fold expression increase (data not shown). The peptides that are shared amongst family members and those distinct to the other three isoforms do not show significant expression change. The marginal distinct A4 evidence resulted from the median ratio of all its constituent peptides being below the significant change threshold in each replicate (Fig. 1a and Supplementary Table 1) .
SILAC relative abundance ratios of proteins were determined using extracted ion chromatograms for each sequenced peptide's light and heavy labelled precursor ion pair in the intervening high-resolution FT-MS scans of the LC-MS/MS runs as previously described 67 . Each individual protein's SILAC ratio was calculated as the median of all SILAC precursor ion ratios corresponding to MS/MS spectra confidently assigned to peptides from that protein. Proteins were considered quantifiable if they were observed in each of 2 replicate experiments with at least 2 SILAC ratios measured in each experiment. Ratios for common laboratory contaminant proteins were filtered out of each data set. As two biological replicate experiments were performed with a light/heavy label-swap between experiments the contaminants were easily recognizable not only by identity but also by extreme quantification ratios with nearly all signals in the light channel. To assign regulated proteins (Fig. 1a and 
